Publication
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitors.
Authors not recorded
Clin Cancer Res2013PMID 24097869stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Neoplasmcivic_curation1.00
- drugGNE-617civic_curation1.00
- geneNAPRTcivic_curation1.00
- variantNAPRT Promoter Hypermethylationcivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 24097869
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NAPRT Promoter Hypermethylation1 | ||||||||
| GNE-617 | Malignant NeoplasmALIAS | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID897Tumor-specific promoter hypermethylation of NAPRT1 led to loss of NAPRT1 expression in most tumor types sensitive to treatment with Nampt inhibitor GNE-617 and nicotinic acid. PMID 24097869 · Shames et al., 2013 · Open in CIViC | civic |